An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results.

ABSTRACT:

SUBMITTER: Ader F 

PROVIDER: S-EPMC9076583 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature